

15. Ziessman HA, Chander A, Clarke JO, Ramos A, Wahl RL. The added diagnostic value of liquid gastric emptying compared with solid emptying alone. *J Nucl Med.* 2009;50:726–731.
16. Ziessman HA, Okolo PI, Mullin GE, Chander A. Liquid gastric emptying is often abnormal when solid emptying is normal. *J Clin Gastroenterol.* 2009;43:639–643.
17. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. *Am J Gastroenterol.* 2013;108:18–37; quiz 38.
18. Bharucha AE, Kudva Y, Basu A, et al. Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. *Clin Gastroenterol Hepatol.* 2015;13:466–476.e461.
19. Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. *Diabetologia.* 1990;33:675–680.
20. Schwarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. *Gastroenterology.* 1997;113:60–66.
21. Sheik A, Anolik J, Maurer AH. Update on serum glucose and metabolic management of clinical nuclear medicine studies: current status and proposed future directions. *Semin Nucl Med.* 2019;49:411–421.
22. Knight LC. Update on gastrointestinal radiopharmaceuticals and dosimetry estimates. *Semin Nucl Med.* 2012;42:138–144.
23. Seidl H, Gundling F, Pfeiffer A, Pehl C, Schepp W, Schmidt T. Comparison of small-bowel motility of the human jejunum and ileum. *Neurogastroenterol Motil.* 2012;24:e373–380.
24. Maurer AH, Camilleri M, Donohoe K, et al. The SNMMI and EANM practice guideline for small-bowel and colon transit 1.0. *J Nucl Med.* 2013;54:2004–2013.
25. Camilleri M, Hasler WL, Parkman HP, Quigley EM, Soffer E. Measurement of gastrointestinal motility in the GI laboratory. *Gastroenterology.* 1998;115:747–762.
26. Camilleri M, Ford AC, Mawe GM, et al. Chronic constipation. *Nat Rev Dis Primers.* 2017;3:17095.
27. Vijgen GH, Schouten R, Bouvy ND, Greve JW. Salvage banding for failed Roux-en-Y gastric bypass. *Surg Obes Relat Dis.* 2012;8:803–808.
28. Antoniou AJ, Raja S, El-Khouli R, et al. Comprehensive radionuclide esophago-gastrointestinal transit study: methodology, reference values, and initial clinical experience. *J Nucl Med.* 2015;56:721–727.
29. Bonapace ES, Maurer AH, Davidoff S, Krevsky B, Fisher RS, Parkman HP. Whole gut transit scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms. *Am J Gastroenterol.* 2000;95:2838–2847.
30. Charles F, Camilleri M, Phillips SF, Thomforde GM, Forstrom LA. Scintigraphy of the whole gut: clinical evaluation of transit disorders. *Mayo Clin Proc.* 1995;70:113–118.
31. Maurer AH, Krevsky B. Whole-gut transit scintigraphy in the evaluation of small-bowel and colon transit disorders. *Semin Nucl Med.* 1995;25:326–338.

## Marta Cremonesi, PhD, 2020 Loevinger–Berman Award Recipient

The SNMMI Medical Internal Radiation Dose (MIRD) Committee announced on January 8 the selection of Marta Cremonesi, PhD, as the 2020 Loevinger–Berman Awardee, recognizing a lifetime of achievements and contributions to medical internal dosimetry. “Marta Cremonesi is an authority in the field of internal dosimetry and one of the pioneers of the initial applications of radiopeptides, in a career that began over 20 years ago. Over time, she has passionately continued her work in all fields of radionuclide therapy, exhibiting both meticulous scientific rigor and extraordinary productivity,” said Lisa Bodei, MD, PhD, a long-time colleague and collaborator. “Her contributions to the definition of the renal impact and tolerability of peptide-receptor radionuclide therapy are considered to constitute the standard of care for anyone involved in this treatment. Marta has defined the field both with her scientific skills and the generosity with which she has shared her knowledge and experience.”

Cremonesi is a medical physicist based in Italy and has served as the Director of the Radiation Research Unit of the European Institute of Oncology of Milan since 2014. Her career shows a dedicated commitment to internal dosimetry for radiopharmaceuticals in general and targeted radionuclide therapy in particular, including several Good Clinical Practice clinical trials using radiopharmaceuticals for diagnosis and therapy. Respected as an authority in the field, she

has presented more than 40 sessions and more than 180 communications and posters at meetings worldwide and has been an author on more than 100 publications, including 11 books.

Cremonesi will be the 21st recipient of the Loevinger–Berman Award since its conception in 1999. The award will be presented at the SNMMI 2020 Annual Meeting in New Orleans, LA, during the Loevinger–Berman Award continuing education session.

This award, sponsored by the Education and Research Foundation for Nuclear Medicine and Molecular Imaging, was established in 1999 by the MIRD Committee in honor of Robert Loevinger, PhD, and Mones Berman, PhD, internal dosimetry pioneers who formulated the MIRD schema for internal dose calculations. The Loevinger–Berman award recognizes innovation and excellence in the nuclear medicine subspecialty of internal radiation dosimetry through research and development, significant publication contributions, or advancement of the understanding of internal dosimetry in relationship to risk and therapeutic efficacy.

*SNMMI*



**Marta Cremonesi,  
PhD**